Emerald Holding recently announced reMind, a new media and events platform committed to building, connecting and educating diverse communities to responsibly grow the business of psychedelics.
Once stigmatized substances, psychedelics are now proving to be powerful tools in the fight against depression, addiction, PTSD, anxiety and neurological disorders. Through live events and digital resources, reMind will unite the researchers, entrepreneurs, investors, policymakers and healthcare professionals at the forefront of the rapidly growing psychedelics field.
reMind will host its first live event — the Psychedelics Business Forum — on November 15 at the Westgate Las Vegas Resort & Casino. The one-day conference and networking event will address the most important topics in the industry today, including the latest drug research, policy changes, investment opportunities, market trends and cultural issues. The Forum takes place alongside MJBizCon, the largest cannabis business conference in the world, and also owned by Emerald Holding, Inc.
The agenda includes:
- “The New Psychedelics Era” — Keynote address by Ethan Nadelmann, founder of the Drug Policy Alliance
- “Cannabis & Psychedelics: Similar Story, Different Trajectory”
- “How the Marketplace Will Evolve”
- “The Future of Psychedelics: Entrepreneurial Perspectives”
- Liana Gillooly, Strategic Initiatives Officer, MAPS
- Simeon Schnapper, Managing Partner, JLS Fund
- Dr. Lynn Marie Morski, Founder of the Psychedelic Medicine Association
- Troy Sia, Senior Advisor on Indigenous Reciprocity, Panacea Plant Sciences
- Sean McAllister, Attorney, McAllister Law Office
- Dustin Robinson, Managing Principal, Iter Investments
reMind is also introducing its companion digital product, remindmedia.com, delivering the latest updates and insights in the field of psychedelics, including legislation, research, investments and business news. Additional resources will follow, including special reports, a community platform, and other forms of original content with the goal of informing and connecting the industry year-round.
“Today, a record 53 million people in the U.S. alone are suffering from a mental illness, such as depression, addiction or PTSD, according to the CDC. With psychedelics-related legislation, investment, and health advancements announced nearly every day, there’s never been a better time to launch a resource like reMind,” said Sara Vaughn, VP, Brand Leader of reMind. “It’s a privilege to connect the brightest minds and most passionate professionals across the business of psychedelics.”
reMind has assembled industry experts to create an advisory board to support its mission and long-term goals. Members include; Kelsey Ramsden, Board Member and former Founder & CEO of MindCure; Amanda Reiman, Chief Knowledge Officer at New Frontier Data and Founder at Personal Plants; and David Heldreth, Scientist, Investor, and CEO, Panacea Plant Sciences.
reMind is also designing a community partnership program to support non-profits, universities, LGBTQ+ and indigenous communities, and other groups and associations that are dedicated to the ethical and sustainable growth of the psychedelics sector.
MJBizCon attendees will be able to learn more about reMind on the MJBizCon expo floor, located on the lower level in business services in booth #1813.